BOSTON–(BUSINESS WIRE)–Outcome Capital, a specialized life sciences and healthcare advisory and investment banking firm, today announced that Getinge has acquired Verrix LLC. Outcome Capital served as the exclusive strategic and financial advisor to Verrix.
Getinge, a global provider of healthcare products and systems designed for improved hospital performance through better hospital sterility management has acquired Verrix LLC. Verrix has developed a rapid biological indicator system with an initial focus on the operating room’s steam sterilization workflow.
“There is a growing demand for biological indicators from healthcare institutions around the world, and what Verrix has developed in this field is truly impressive, setting new standards of speed and accuracy. We are looking forward to adding this new infection control technology to our customer offering,” said Stéphane Le Roy, President Surgical Workflows at Getinge.
“We are excited to be part of the Getinge team. This transaction strategically secures our global market entry into the hospital sterility monitoring segment. We believe that Verrix’s EVA platform will also enable the development of future biological indicators to augment Getinge’s expertise and commercial offerings across the healthcare and life science segments,” said Sami El-Saden, Verrix CEO.
About Outcome Capital
Outcome Capital is a highly specialized life sciences and healthcare advisory and investment banking firm, providing innovative companies with a value-added, market-aligned approach to mergers & acquisitions, partnering and corporate finance. The firm leverages its proven ‘strategy-led execution’ approach to value enhancement by assisting management teams and their boards in navigating both financial and corporate markets and implementing the best path for success. The firm’s strength stems from its multi-disciplinary, industry experts who draw from their broad relationships and a wide range of scientific, operational, strategic and transactional expertise across the value chain. Comprised of former CEOs, business development executives, venture capitalists, PhD/MD-level scientists and clinicians, and experienced commercialization experts, Outcome’s team is driven to propel innovation from bench to bedside.
With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions aiming to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs over 10,000 people worldwide and the products are sold in more than 135 countries.
Verrix is a San Clemente, Calif.-based medical device company that is using the most advanced technologies to help protect patients from healthcare-associated infections. The foundational sterility assurance technology, originally discovered at NASA’s Jet Propulsion Laboratory, integrates cutting-edge optical physics, chemistry spectroscopy, and molecular biology. Based on scientific expertise and close partnerships with healthcare professionals, Verrix is developing market-changing solutions for sterility assurance, environmental monitoring, and infection control.
BOSTON–(BUSINESS WIRE)–Outcome Capital, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced that NanoHive Medical, LLC closed on an oversubscribed Growth Financing round to support its product expansion and commercialization efforts. Outcome Capital served as exclusive strategic and financial advisor for the transaction. The use of proceeds will be dedicated […]Read More
Outcome Capital Life Science Market Pulse April 2022 Click to view our LifeSciences Pulse NewsletterDownload